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Abstract
Background: Cardiac events (CEs) are among the most serious late effects following childhood cancer treatment. To
establish accurate risk estimates for the occurrence of CEs it is essential that they are graded in a valid and consistent
manner, especially for international studies. We therefore developed a data-extraction form and a set of flowcharts to grade
CEs and tested the validity and consistency of this approach in a series of patients.
Methods: The Common Terminology Criteria for Adverse Events version 3.0 and 4.0 were used to define the CEs. Forty
patients were randomly selected from a cohort of 72 subjects with known CEs that had been graded by a physician for an
earlier study. To establish whether the new method was valid for appropriate grading, a non-physician graded the CEs by
using the new method. To evaluate consistency of the grading, the same charts were graded again by two other non-
physicians, one with receiving brief introduction and one with receiving extensive training on the new method. We
calculated weighted Kappa statistics to quantify inter-observer agreement.
Results: The inter-observer agreement was 0.92 (95% CI 0.80–1.00) for validity, and 0.88 (0.79–0.98) and 0.99 (0.96–1.00) for
consistency with the outcome assessors who had the brief introduction and the extensive training, respectively.
Conclusions: The newly developed standardized method to grade CEs using data from medical records has shown excellent
validity and consistency. The study showed that the method can be correctly applied by researchers without a medical
background, provided that they receive adequate training.
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Introduction
Due to the improvement in treatment protocols and new
treatment modalities survival from childhood cancer is currently
around 80% [1]. Inherent to this improvement in childhood
cancer survival is the growing population of childhood cancer
survivors (CCS). However, around 75% of survivors will have at
least one late adverse effect (e.g. endocrine, neurologic or
psychosocial late adverse effects) induced by the cancer treatment
[2]. Knowledge of the incidence and risk factors for specific late
adverse effects is essential, as it contributes to optimal follow-up
care for survivors and recommendations for less toxic treatments
for future childhood cancer patients. Frequent late effects within
CCS are cardiac events (CE), such as heart failure, ischemia,
pericarditis, valvular disease and arrhythmia, all of which cause
long-term morbidity and early mortality [3,4]. After a median
follow-up time of more than thirteen years, the cumulative
incidence of symptomatic heart failure is 1.7–2%, ischemia 0.44–
0.7%, pericarditis 0.14–1.3%, valvular disease 0.44–1.6% and
arrhythmia 0.66% [3,5].
A major limitation in current studies of CEs is the lack of
uniform outcome definitions for the events in question. Definitions
vary between research groups; even those within the same country.
In addition, the CEs are often graded by several physicians (from
different specialities), based on expert opinion, and without a clear
grading protocol [3,5–8]. For example, in a previous study of van
der Pal et al. [3] two authors (both physicians) graded CEs using
the Criteria for Adverse Events (CTCAE) version 3.0 (heart
failure, ischemia, pericarditis, valvular disease and arrhythmia
grade 3–5) consulting a cardiologist when uncertain [3]. On the
other hand, Mulrooney et al. [5] used self-reported CEs. Survivors
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were asked if they had ever been told by a doctor or other
healthcare professional, that they have, or have had, a CE (i.e.
heart failure, myocardial infarction, valvular abnormalities or
pericardial disease). Within this study the severity of the CEs could
not be established. Therefore, the lack of uniform outcome
definitions for CEs makes it impossible to compare the results of
existing studies and to summarize the evidence, thus making it
difficult to make recommendations for clinical practice. Further-
more, Atkinson et al. [9] showed that agreement between different
clinicians when reporting adverse events is ‘‘moderate’’ at best,
even when clear outcome definitions (i.e. the CTCAE) are used.
This study shows that even uniform outcome definitions for CEs
are not sufficient and that there is a need for a clear grading
protocol.
At this moment a large pan-European study is being conducted;
PanCareSurFup (PanCare Childhood and Adolescent Cancer
Survivor care and Follow-up studies (PCSF)). One of the main
objectives of PCSF is to identify CCS who have developed a
symptomatic CE. Seven different European countries (the United
Kingdom, France, Italy, Switzerland, Slovenia, Hungary and the
Netherlands) will contribute cardiac data to this study and the
incidence and absolute risk of cardiac disease among 5-year CCS
will be determined. Furthermore, a nested case-control study will
be undertaken to investigate the nature of the dose-response
relationship between cumulative dose of specific anti-cancer drugs,
cumulative dose of irradiation, and the risk of a CE. Outcome
assessors will have different specialties, i.e. physicians and non-
physicians (e.g. data managers or research nurses). To adequately
analyse the data from the different countries the CEs need to be
graded and validated in a uniform manner across Europe.
The aim of this study was to test the validity and consistency of a
newly developed data-extraction form in combination with a
flowchart to grade CEs in a group of CCS with a known CE.
Methods
Study population
We included CCS with a previously defined symptomatic CE
from the cohort described in van der Pal et al. 2012 [3]. This
cohort consisted of 1362 5-year CCS who were diagnosed with
childhood cancer in the Emma’s Children Hospital/Academic
Medical Center between January 1966 and January 1996.
Seventy-two survivors were suspected of a symptomatic CE
during follow-up. After careful review forty-two patients were
coded as a symptomatic CE (CTCAEv3.0 grade $3) and 30
patients were coded as an asymptomatic CE (CTCAEv3.0 grade
#2). Our outpatient clinic for follow-up after treatment for
childhood cancer was reviewed by the Institutional Review Board
of the Academical Medical Center in Amsterdam and the study
was deemed as patient care and was therefore exempt from the
need for ethical approval. Throughout patient care, acquired
outcomes are used for scientific research to evaluate care.
Additionally, CCS gave informed consent for data collection from
the medical records. Patient records were anonymized and de-
identified prior to analysis.
The new method: data-extraction form/flowchart
method for CEs
We developed a standardized data-extraction form (see SI 1), a
set of flowcharts (one for each CE, i.e. heart failure, ischemia,
pericarditis, valvular disease and arrhythmia; see SI 1), a manual
with background information and a training presentation. The
method is developed to distinguish between a CE of grade #2 and
grade 3, 4 and 5. Grade #2 is predominantly asymptomatic. The
method consists of two steps; 1) extraction of all relevant
information from the available medical records, questionnaire
(patient or physician) or interview using the standardized data
extraction form and 2) assignment of a grade to the CEs using the
appropriate flowchart. In Figure 1 the flowchart of heart failure is
shown as an example. Each flowchart is constructed in the same
manner; a step diagram and clarifying text blocks. We used a
combination of the CTCAEv3.0 and CTCAEv4.0 for the
definitions of CEs (see Table 1). Besides the data-extraction form
and flowcharts we wrote a manual, including background
information on the different CEs, and an extensive explanation
on the use of the method (see File S1, Table S1, Figure S1–S5).
Finally outcome assessors attended a presentation (see Presentation
S1) to explain the method in more detail with the use of examples.
Validity and consistency of the data-extraction form/
flowchart method for CEs
In Figure 2 the methodology for testing the validity and
consistency is schematically shown.
The validity of our new method was tested by comparing the
CE grading outcome of the physician of the forty randomly
selected patients from the seventy-two CCS from a previous study
[3], with the new grading outcome using the data-extraction
form/flowchart method as graded by a non-physician. This non-
physician had been involved in the development of the new
method, but could be considered as a non-physician who had
received an extensive training.
The consistency of the new method was tested by comparing the
grading of the non-physician involved in the development of the
new method with the grading of two other non-physicians, of
whom one who had received a brief introduction to the method,
based on the text below the flowcharts, and a second had received
extensive training on the new method by means of the full manual
and a presentation with an example case-study. In the first
consistency test we compared the grading of the non-physician
involved in the development of the method with the grading of the
non-physician who received solely a brief introduction. In the
second consistency test we compared the grading of the non-
physician involved in the development of the method with the
grading of the non-physician who received an extensive training.
In this way we were able to test the robustness of the new method
as well as the additional value of the extensive training. The first
consistency test shows if the method on its own is sufficient for
consistent grading of cardiac events. By comparing the results of
the first consistency test with those of the second consistency test
we can determine the additional value of the extensive training.
The non-physicians were blinded for the results of the physician
and the other non-physicians.
Data extraction
The necessary information was taken from medical charts. The
medical charts were readily available since they were already
collected for the study of van de Pal et al. [3]. To properly grade
the CE information was needed on symptoms, diagnostic tests,
medication and surgery. The goal was to get complete data on all
those subjects for each CE.
Statistical analysis
To determine the agreement between the different outcome
assessors we calculated a weighted Kappa [12,13]. The weighted
Kappa is used when there are several ordered grades and is
calculated with the following formula: (probability of observed
matches - probability of expected matches)/(1 - probability of
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Figure 1. Flowchart heart failure. 1a. The first question is ‘‘Symptoms1?’’, ‘‘number 10 refers to block 1 under the step diagram, in this block
symptoms of heart failure are shown, so the user knows which symptoms could occur; When the answer is ‘‘NO’’. 1b. Is the ‘‘EF,40%-20% or the FS,
15%’’ YES grade 3 heart failure. NO grade #2 heart failure. When the answer is ‘‘YES’’ Go to question ‘‘Responsive to intervention2?’’ 2.
Question ‘‘Responsive to intervention2?’’, block 2 in which common interventions for heart failure are shown; When the answer is ‘‘NO’’ grade 4 heart
failure. When the answer is ‘‘YES’’ grade 3 heart failure. When it is ‘‘UNKNOWN’’ go to question ‘‘ Device3, life threatening consequences4 or heart
transplant?’’. 3. Question ‘‘ Device3, life threatening consequences4 or heart transplant?’’, block 3 under the step diagram, in this block devices used as
treatment for heart failure are shown. In block 4 the life threatening consequences associated with heart failure are stated; When the answer is ‘‘NO’’
grade 3 heart failure. When the answer is ‘‘YES’’ grade 4 heart failure. Ref. [10,11]. ICD-10 = International classification of disease version 10.
EF = ejection fraction. SF = shortening fraction. CRT-P or D= cardiac resynchronisation therapy pacemaker or defibrillator. ICD= implantable
cardioverse defibrillator. LVAD= left ventricular assistance device.
doi:10.1371/journal.pone.0100432.g001
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expected matches). The disagreements are weighted according to
their squared distance from perfect agreement. R was used to
calculate the weighted Kappa and 95% confidence intervals [14].
Values of Kappa between 0.40 and 0.59 are considered to reflect a
fair agreement, between 0.60 and 0.74 to reflect a good agreement
and 0.75 or more to reflect an excellent agreement [15].
Results
Study population
The median age of the forty persons (18 females), was 9.9 years
(range 0.6–17.2) at the time of cancer diagnosis and 31.1 years
(range 13.5–46.4) at the time of follow-up, with a median follow-
up time of 21.6 years (range 5.1–36.1) since diagnosis. Fifteen
subjects (37.5%) had received anthracyclines alone, ten subjects
(25%) radiotherapy involving the heart region and eleven subjects
(27.5%) anthracyclines and radiotherapy involving the heart
region. Four subjects (10%) had not received any known
cardiotoxic treatment. Nineteen subjects (47.5%) had been
diagnosed with heart failure (grade #2 n= 6, grade 3 n= 8,
grade 4 n= 2, grade 5 n= 3) as first occurring CE, three subjects
(7.5%) with ischemia (grade 3 n= 2, grade 4 n=1), one subject
(2.5%) with pericarditis (grade 4 n= 1), fourteen subjects (35%)
with valvular disease (grade #2 n= 11, grade 3 n= 2, grade 4
n=1) and three subject (7.5%) with arrhythmia (grade #2 n= 1,
grade 3 n= 2).
Validity and consistency of the data-extraction form/
flowchart method for CEs
The results of the validity test are shown in Table 2. The inter-
observer agreement for the comparison between the grading of the
main non-physician and the grading of the physician in the
previous study [3] was 0.92 (0.80–1.00). Three CEs were graded
differently: two of them were graded as grade 3 by the non-
physician and as grade #2 in the previous study [3]. The third CE
was graded differently due to incomplete medical records.
Table 1. Definitions of cardiac events (using CTCAEv3.0 and CTCAEv4.0).
Grade 3 Grade 4 Grade 5
Heart failure Symptomatic CHF responsive
to intervention, or
EF,40%-20%, or SF,15%
Refractory CHF or poorly controlled;
EF,20%; intervention such as ventricular
assist device, ventricular reduction
surgery, or heart transplant indicated;
life threatening consequences*
Death due to
heart failure
Ischemia Symptomatic and testing consistent
with ischemia or unstable angina or
intervention needed
Myocardial infarction; life
threatening consequences*
Death due to
ischemia
Pericarditis With physiological consequences
(e.g. pericardial constriction or
pericardial effusion)
With life threatening
consequences (e.g. hemodynamic
comprise)
Death due to
pericarditis
Valvular
mdisease
Symptoms of severe regurgitation
or stenosis, symptoms controlled
with interventions
Life threatening consequences or
intervention (e.g. valve
replacement or valvuloplasty)
indicated
Death due to
valvular disease
Arrhythmia Symptomatic and incompletely
medically controlled or
controlled with device (e.g.
pacemaker, ICD or CRT)
Life threatening consequences
(e.g. arrhythmia associated with
CHF, hypotension, syncope, shock)
Death due to an
arrhythmia
*as reported in the Criteria for Adverse Events (CTCAE)v4.0.
CHF= congestive heart failure.
EF = ejection fraction.
SF = shortening fraction.
ICD= implantable cardioverse defibrillator.
CRT = cardiac resynchronisation therapy.
Note: If a CE doesn’t comply with any of these criteria, it should be graded as grade #2.
doi:10.1371/journal.pone.0100432.t001
Table 2. Result for validity (physician (P) vs non-physician (NP).
P
Grade #2 Grade 3 Grade 4
NP Grade #2 17 0 0
Grade 3 2* 12 0
Grade 4 0 0 5
*Grade unknown n= 1 not included.
Kappa=0.92 (0.80–1.00).
doi:10.1371/journal.pone.0100432.t002
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The results of the two consistency assessments are presented in
Table 3 and 4. The inter-observer agreement for the comparison
between the non-physician involved in the development of the new
method and the results of a non-physician who only received a
brief introduction of the method was 0.88 (0.79–0.98). Eight CEs
were graded differently (Table 2b), but always in an adjacent
severity category.
The inter-observer agreement for the comparison between the
non-physician involved in the development of the new method and
the results of a non-physician who received extensive training on
the new method by means of the above mentioned manual and
presentation was 0.99 (0.96–1.00). Only one CE was graded
differently (Table 2c).
Discussion
This study demonstrates that our new standardised method for
grading CEs in CCS using a data-extraction form and a set of
flowcharts is valid and consistent. The random selection of the
known cases resulted in a variation of CEs including different
diagnoses and different levels of severity; therefore all five
flowcharts were tested in this current study. With this method
non-physicians can score CEs in an accurate manner. However,
Figure 2. Methodology of testing the validity and consistency of the data-extraction form/flowchart method for CEs.
doi:10.1371/journal.pone.0100432.g002
Table 3. Result first consistency assessment (non-physician (NP) vs non-physician (brief introduction) (NPB)).
NP
Grade #2 Grade 3 Grade 4
NPB Grade #2 14 2 0
Grade 3 3 12 3
Grade 4 0 0 2
Kappa=0.88 (0.79–0.98).
doi:10.1371/journal.pone.0100432.t003
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the best results from non-physicians were achieved when extensive
training was given. Not all relevant data was extracted by the non-
physician who received only a brief introduction of the method,
resulting in a lower inter-observer agreement. The non-physician
who received only a brief introduction of the method also had a
limited knowledge of CEs. None of the previous studies focussing
on CEs after cancer treatment had used a standardised method for
the definition of the outcomes as described in this paper. The
extraction form describes very specifically the information that is
essential in order to grade the CE. This information can often be
extracted from test results or letters, which are easy to interpret.
Therefore, a strength of our method is that the invested time for
retrieving necessary information for grading the CEs is minimal.
A limitation of this current study is that although the data-
extraction/flowchart method may be used with several types of
data (e.g. questionnaire, interviews or information from doctors),
the current study only validated the method through the use of
medical charts. With this study we wanted to confirm in principle
that the data-extraction form/flowchart method is a valid and
consistent method of grading a CE. The completeness in medical
charts, compared to other sources of data, can be considered a
benefit for this purpose. The external validity of the results of this
study has not yet been tested in other institutes.
PanCareSurFup is a large pan-European study, of which one of
the main objectives is to collect symptomatic CEs. Based on our
findings, we believe that the data-extraction form/flowchart
method can be safely used to consistently grade the CEs, across
the different European countries. The current method is
developed for CEs, but the CTCAE is available for adverse
events of different organ systems. A similar method could be
developed for different other organs systems, which could then be
applied in collaborative research.
We conclude that our newly developed method is a valid and
consistent way to grade CEs. This method can be used by assessors
with different medical background, provided that they receive
proper instruction about the method, for which the manual and
the training presentation are available.
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Figure S1 Flowchart Heart failure.
(TIF)
Figure S2 Flowchart Ischemia.
(TIF)
Figure S3 Flowchart Pericarditis.
(TIF)
Figure S4 Flowchart Valvular disease.
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Figure S5 Flowchart Arrhythmia.
(TIF)
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File S1 Manual text including background information on the
different CEs, and an extensive explanation on the use of the
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